Table 1.
Baseline clinical characteristics at registration of patients with and without progression to end‐stage hypertrophic cardiomyopathy
| Overall cohort n = 157 | Progression to end‐stage HCM (+) n = 13 | Progression to end‐stage HCM (−) n = 144 | P | |
|---|---|---|---|---|
| Age at registration, years | 59.9 ± 14.2 | 61.2 ± 15.8 | 59.5 ± 14.1 | 0.734 |
| Gender: male, n (%) | 104 (66%) | 11 (85%) | 93 (65%) | 0.221 |
| Age at diagnosis, years | 53.5 ± 15.8 | 46.2 ± 16.9 | 54.1 ± 15.6 | 0.086 |
| Follow‐up period, years | 6.3 ± 2.8 | 7.5 ± 2.0 | 6.1 ± 2.8 | 0.039 |
| Family history of HCM, n (%) | 51 (32%) | 7 (54%) | 44 (31%) | 0.120 |
| Presence of AF, n (%) | 28 (18%) | 5 (38%) | 23 (16%) | 0.057 |
| NYHA functional class: ≥II, n (%) | 56 (36%) | 7 (54%) | 49 (34%) | 0.225 |
| Echocardiographic data at registration | ||||
| Subtype, n (%) | 0.065 | |||
| HOCM | 23 (15%) | 0 (0%) | 23 (16%) | |
| MVO | 6 (4%) | 0 (0%) | 6 (4%) | |
| Apical HCM | 24 (15%) | 0 (0%) | 24 (17%) | |
| Others | 104 (66%) | 13 (100%) | 91 (63%) | |
| Presence of LV outflow obstruction, n (%) | 23 (15%) | 0 (0%) | 23 (16%) | 0.218 |
| LV ejection fraction, % | 70.0 ± 7.8 | 59.6 ± 6.0 | 71.0 ± 7.3 | <0.001 |
| LV end‐diastolic diameter, mm | 45.4 ± 6.0 | 49.8 ± 5.8 | 45.0 ± 5.8 | 0.005 |
| Maximum LV wall thickness, mm | 20.2 ± 3.8 | 19.5 ± 4.4 | 20.3 ± 3.8 | 0.508 |
| Left atrial diameter, mm | 43.9 ± 7.0 | 49.8 ± 7.4 | 43.4 ± 6.7 | 0.001 |
| E/e′ (septal) | 12.6 ± 8.6 | 12.8 ± 4.2 | 12.6 ± 8.9 | 0.954 |
| E/e′ (lateral) | 8.7 ± 4.8 | 8.3 ± 2.5 | 8.8 ± 4.9 | 0.735 |
| Hs‐cTnT value, ng/mL | 0.019 ± 0.020 | 0.033 ± 0.034 | 0.018 ± 0.019 | 0.012 |
| Elevated hs‐cTnT value: >0.014 ng/mL, n (%) | 78 (50%) | 11 (85%) | 67 (47%) | 0.009 |
AF, atrial fibrillation; HCM, hypertrophic cardiomyopathy; HOCM, hypertrophic obstructive cardiomyopathy; hs‐cTnT, high‐sensitivity cardiac troponin T; LV, left ventricular; MVO, midventricular obstruction; NYHA, New York Heart Association.
Values are mean ± SD and n (%).